Takeda Pharmaceutical (NYSE:TAK) Insider Nicola Deidre Petal Greenway Sells 6,774 Shares of Stock

Posted by Brian Himes on Aug 12th, 2026

Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) insider Nicola Deidre Petal Greenway sold 6,774 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $115,835.40. Following the sale, the insider directly owned 53,029 shares of the company’s stock, valued at approximately $906,795.90. This represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock traded down $0.06 during trading hours on Wednesday, reaching $17.42. 2,004,364 shares of the stock were exchanged, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The stock has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm’s 50 day moving average is $16.49 and its 200 day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

View Our Latest Analysis on Takeda Pharmaceutical

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical in the second quarter valued at about $163,000. GAMMA Investing LLC raised its holdings in shares of Takeda Pharmaceutical by 10.7% in the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock worth $222,000 after acquiring an additional 1,338 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Takeda Pharmaceutical by 10.8% in the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after acquiring an additional 4,169 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 10.5% in the first quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after acquiring an additional 2,343 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its stake in shares of Takeda Pharmaceutical by 9.6% during the first quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after acquiring an additional 2,640 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.